Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Corneal Neovascularization Overview 6 Therapeutics Development 7 Pipeline Products for Corneal Neovascularization - Overview 7 Pipeline Products for Corneal Neovascularization - Comparative Analysis 8 Corneal Neovascularization - Therapeutics under Development by Companies 9 Corneal Neovascularization - Therapeutics under Investigation by Universities/Institutes 10 Corneal Neovascularization - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Corneal Neovascularization - Products under Development by Companies 13 Corneal Neovascularization - Products under Investigation by Universities/Institutes 14 Corneal Neovascularization - Companies Involved in Therapeutics Development 15 Amakem NV 15 Gene Signal International SA 16 Sirnaomics, Inc. 17 Corneal Neovascularization - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 aganirsen - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 AMA-0526 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Gene Therapy to Activate Raver-2 Protein for Corneal Neovascularization - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Gene Therapy to Inhibit Vascular Endothelial Growth Factor A for Corneal Neovascularization - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 JDE-006 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Netrin-4 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 NOV C-ter - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Recombinant Protein for Oncology and Ophthalmology - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 STP-601 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Corneal Neovascularization - Recent Pipeline Updates 37 Corneal Neovascularization - Dormant Projects 38 Corneal Neovascularization - Product Development Milestones 39 Featured News & Press Releases 39 May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation. 39 Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure 41 Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth 41 Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44

List of Tables Number of Products under Development for Corneal Neovascularization, H1 2016 7 Number of Products under Development for Corneal Neovascularization - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Corneal Neovascularization - Pipeline by Amakem NV, H1 2016 15 Corneal Neovascularization - Pipeline by Gene Signal International SA, H1 2016 16 Corneal Neovascularization - Pipeline by Sirnaomics, Inc., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Corneal Neovascularization Therapeutics - Recent Pipeline Updates, H1 2016 37 Corneal Neovascularization - Dormant Projects, H1 2016 38 List of Figures Number of Products under Development for Corneal Neovascularization, H1 2016 7 Number of Products under Development for Corneal Neovascularization - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25

Amakem NV Gene Signal International SA Sirnaomics, Inc.